血液検査の世界市場予測(~2021):技術別(核酸増幅、(rPCR)、ELISA、(CLIA、蛍光アッセイ)、迅速試験、NGS、ウエスタンブロット)、製品別、需要先別...市場調査レポートについてご紹介

【英文タイトル】Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Introduction (Page No. – 14)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 17)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown & Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 24)
3.1 Introduction
3.2 Current Scenario
3.3 Conclusion

4 Premium Insights (Page No. – 29)
4.1 Blood Screening Market
4.2 Blood Screening Market, By Region & Technology

5 Market Overview (Page No. – 31)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Number of Blood Donations and Blood Donors
5.2.1.2 Increasing Demand of Donated Blood
5.2.1.3 Rising Prevalence of Infectious Diseases
5.2.1.4 Growing Affordability and Adoption of NAT for Blood Screening
5.2.1.5 Rising Awareness Regarding the Safety of Donated Blood
5.2.2 Restraints
5.2.2.1 Capital Expenditure and Operating Costs of NAT
5.2.2.2 Lack of Regulations Mandating the Use of NAT in Developing Countries
5.2.2.3 Emergence of Alternative Technologies
5.2.3 Opportunities
5.2.3.1 Pathogen Reduction Technology
5.2.3.2 Multiplex Tests
5.2.3.3 Emerging Economies
5.2.4 Challenges
5.2.4.1 Price Reduction

6 Blood Screening Market, By Technology (Page No. – 38)
6.1 Introduction
6.2 Blood Screening Market, By Volume (Number of Tests Conducted)
6.3 Nucleic Acid Test (NAT)
6.3.1 Transcription-Mediated Amplification (TMA)
6.3.2 Real-Time Polymerase Chain Reaction (PCR)
6.4 Enzyme-Linked Immunosorbent Assay (ELISA)
6.4.1 ELISA Market, By Platform
6.4.1.1 Chemiluminescence Immunoassay (CLIA)
6.4.1.2 Fluorescence Immunoassay (FIA)
6.4.1.3 Colorimetric Immunoassay (CI)
6.4.2 ELISA Market, By Generation
6.4.2.1 First-Generation ELISA
6.4.2.2 Second-Generation ELISA
6.4.2.3 Third-Generation ELISA
6.4.2.4 Fourth-Generation & Above
6.5 Rapid Tests
6.6 Western Blot Assay
6.7 Next-Generation Sequencing (NGS)

7 Blood Screening Market, By Product and Service (Page No. – 56)
7.1 Introduction
7.2 Reagents & Kits
7.2.1 NAT Reagents & Kits
7.2.1.1 Enzymes and Polymerases
7.2.1.2 Standards and Controls
7.2.1.3 Probes and Primers
7.2.1.4 Buffers, Nucleotides and Solutions
7.2.1.5 Labeling and Detection Reagents
7.2.2 ELISA Reagents & Kits
7.2.2.1 Immunosorbents
7.2.2.2 Controls
7.2.2.3 Conjugates (Antigen Or Antibody-Conjugated Enzyme)
7.2.2.4 Substrates (Of Enzymes)
7.2.2.5 Sample Diluents and Wash Solutions
7.2.3 Other Reagents
7.3 Instruments
7.3.1 Rental Purchase
7.3.2 Outright Purchase
7.4 Software and Services

8 Blood Screening Market, By End User (Page No. – 68)
8.1 Introduction
8.2 Blood Banks
8.3 Hospitals

9 Blood Screening Market, By Region (Page No. – 72)
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe (RoE)
9.4 Asia
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Rest of Asia (RoA)
9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. – 104)
10.1 Overview
10.2 Market Share Analysis
10.2.1 Market Share Analysis for NAT
10.2.2 Blood Screening Market Share Analysis
10.3 Competitive Situations and Trends
10.3.1 Product Launches
10.3.2 Regulatory Approvals
10.3.3 Agreements
10.3.4 Partnerships
10.3.5 Acquisitions
10.3.6 Expansions

11 Company Profiles (Page No. – 113)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 Introduction
11.2 Grifols
11.3 F. Hoffmann-La Roche
11.4 Abbott Laboratories
11.5 Biomérieux
11.6 Bio-Rad Laboratories, Inc.
11.7 Siemens Healthineers (A Subsidiary of Siemens AG)
11.8 Ortho Clinical Diagnostics, Inc.
11.9 Thermo Fisher Scientific, Inc.
11.10 Beckman Coulter (A Subsidiary of Danaher Corporation)
11.11 Becton, Dickinson and Company

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. – 139)
12.1 Discussion Guide
12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.3 Introducing RT: Real-Time Market Intelligence
12.4 Available Customizations
12.5 Related Reports
12.6 Author Details


【レポート販売概要】

■ タイトル:血液検査の世界市場予測(~2021):技術別(核酸増幅、(rPCR)、ELISA、(CLIA、蛍光アッセイ)、迅速試験、NGS、ウエスタンブロット)、製品別、需要先別
■ 英文:Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021
■ 発行日:2016年12月21日
■ 調査会社:MarketsandMarkets
■ 商品コード:MAM-MD-3687
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。